Skip to content

About Artrya

Founded with a mission to save lives, our world-class team of cardiology and technology experts drive our vision for better detection of a major worldwide killer – coronary artery disease.

Image of perth

We are Australian.

Artrya is an AI-driven health-tech company, founded in 2018, and brought to life on the shores of Perth, Australia. Artrya was developed by John Konstantopoulos and John Barrington, who came together with a mutual passion for disruptive technologies and improving health outcomes across the globe. Artrya sees heart disease in a new way, using data-driven solutions to assist cardiovascular diagnosis.

Image of doctor and patient

We are pioneers.

We are forging a new way to detect the fatal cause of heart attacks, which is vulnerable plaque. We are doing it in a way that is better for patients, more effective for healthcare professionals and more efficient for healthcare systems.

Modern medicine

We know heart disease diagnosis is not optimal.

Heart disease diagnosis has not changed significantly in more than 50 years. That’s two generations that have continued to be in the dark about the real cause of heart disease deaths. Traditional diagnostic processes to assess stenosis have avoided sophisticated analysis because it was time-consuming and required significant manual inputs.

Patient Image

We are changing that.

Our AI-solution helps bring the benefits of new and emerging diagnostic metrics to clinical practice. This is changing the diagnostic paradigm.

Patient image

We are shining a light on cardiovascular diagnosis.

We want to bring about nothing less than a transformation of cardiovascular disease care.

Artrya. Your partner in AI-driven healthcare.

Photo of Artrya Executive Team

What we do

Artrya is an Australian health-tech company, founded in 2018. We see heart disease in a new way, using data-driven solutions to assist cardiovascular diagnosis.

We collaborate with radiologists, cardiologists, and healthcare professionals to provide personalised cardiovascular-health risk assessments within minutes. Our innovative diagnostic support solution accurately assesses and detects vulnerable, high-risk plaque, in real time, without the need for invasive interventions.

We enable the risk stratification of patients and with this, provide a prioritisation tool to clinicians so they can get the right treatment to the right patient at the right time. This early indication of the superior predictor of heart attack, and near-immediate pathway to the right treatment option, has the potential to reduce the number of major adverse cardiac events each year.

Our safe and non-invasive heart-disease solution will allow improved access to informed decision-making for cardiologists and patients.

Accurate. Safe. Fast. Life-saving.

Logo

The heart behind our name

Meaning of Artrya

Ar-tree-a (phonetic)

Artrya is a play on words of ‘artery,’ the vessel which takes oxygen-rich blood from the heart to other parts of the body. It is based on the Greek word aρτηρiα (arteria) meaning ‘air’ and ‘to keep’. This underpins our mission to use advanced, AI-based technology to reduce the number of heart attacks that occur around the world each year and, fundamentally, save lives.

Artrya's Journey

Timeline

Artrya acknowledges the Traditional Custodians of Country throughout Australia and their connections to land, sea and community. We pay our respect to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.

We acknowledge the Whadjuk Noongar people, Traditional Custodians of the land on which the Artrya office operates.

MTPConnect logo

MTPConnect

Artrya Salix has been developed with funding from MTPConnect, an Australian incubator for medical technologies. Other private investors have also assisted with research and development funding.